News und Analysen
3 Companies Building the World of Tomorrow
It's always intriguing to think about what new technologies the future will bring. But what you might not realize is that many of the building blocks of tomorrow are already in place. And lucky for
Illumina Inc. Blows Past Guidance in Second Quarter With Strong NovaSeq Demand
Illumina Inc. (NASDAQ: ILMN) started out 2017 on a positive note by beating its first-quarter revenue guidance and coming in at the upper end of its earnings guidance. However, there were a few
Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo
Merck & Co (NYSE: MRK) and Bristol-Myers Squibb (NYSE: BMY) are engaged in a battle of sorts. The two won FDA approval for new non-small cell lung cancer therapies in 2015 that work similarly, and
12 Numbers in Pfizer's Q2 Update More Important Than Its Revenue Decline
Pfizer (NYSE: PFE) announced its second-quarter results before the market opened on Tuesday. And investors yawned -- at least for the most part.Many of the headlines about the big drugmaker's
2 Dividend-Growth Stocks That Are Minting Money
If you're looking for a good dividend stock for the long term, it's important to look beyond current dividend yields to the company's prospects for growth and the strength of its free cash flow. A
Why Clovis Oncology Tumbled 13.5% Today
After disclosing that it's entered into a pact with Bristol-Myers Squibb (NYSE: BMY) on its cancer-fighting drug Rubraca, shares in Clovis Oncology (NASDAQ: CLVS) lost 13.5% of their value Monday.
Why Clovis Oncology, Gulfport Energy, and Hertz Global Holdings Slumped Today
The stock market saw a lot of indecision on Monday, as major benchmarks moved in different directions. The Nasdaq Composite was weaker than most of its peers, but the Dow Jones Industrials jumped to
A Beat From Qiagen NV, but Only Half a Raise
It was another solid quarter for Qiagen (NASDAQ: QGEN) as the maker of diagnostic and scientific products continues to post decent revenue growth while getting more efficient, which drives income to
3 Things You Can Expect With Pfizer's Q2 Results
There was good news and bad news for Pfizer (NYSE: PFE) the last time it reported quarterly results. In May, the big drugmaker announced earnings for the first quarter that beat analysts' estimates
What's Next for AstraZeneca and Its Dividend?
Just over three summers ago, AstraZeneca plc (NYSE: AZN) CEO Pascal Soriot convinced shareholders to reject a generous buyout offer from Pfizer with promises that drugs in its pipeline would deliver
3 Biotech Stocks for Enterprising Investors
The biotech sector isn't for the faint of heart. While investors can strike it rich if they get lucky, they can also lose a bundle if things don't go according to plan. Given the risk, it can take a
McCain Pulls the Plug on Obamacare "Skinny Repeal" Without Replacement
Republicans have been fighting to repeal and replace the Affordable Care Act since it was passed by Democrats in 2010. After winning Congress and the White House last November, many republicans
Here's Why Align Technology Marched Higher Again Today
Shares of Align Technology, Inc. (NASDAQ: ALGN), an orthodontic-device company, rose about 10% during Friday's session. Record results released after the bell on Thursday should keep investors smiling
Celgene Corporation Continues to Get It Done
Celgene (NASDAQ: CELG) continues to grow revenue with its top-three drugs all experiencing sales growth of at least 20% year over year in the second quarter. The solid quarter allowed management to
Here's Why NuVasive Is Tanking Today
After NuVasive (NASDAQ: NUVA), a medical device maker focused on minimally invasive spine surgery, reported mixed second-quarter earnings results and announced a shake-up in its executive team, its
3 Value Stocks Senior Citizens Should Consider Buying Today
News flash, seniors: the average American's life expectancy has increased by roughly a decade since you were born, meaning now more than ever you'll need to ensure you won't outlive your money. This
Vertex Pharmaceuticals Incorporated Chugs Along
Vertex Pharmaceuticals (NASDAQ: VRTX) keeps chugging along, generating increased sales for its two cystic fibrosis drugs as it gains additional approvals to treat more patients, and producing clinical
Abiomed, Inc. Starts Its Fiscal Year on a High Note
Abiomed (NASDAQ: ABMD), a medical-device company focused on minimally invasive heart pumps, reported its fiscal first-quarter earnings on Thursday, July 27. The company's results proved yet again that
Align Technology Again Makes Investors Smile With a Record Second Quarter
Align Technology's (NASDAQ: ALGN) first quarter was one for the record books. On Thursday, Align announced its second-quarter results. The orthodontic-device maker reported all-time high revenue
Cerner Corporation Meets Expectations in Second Quarter With Solid Recurring Revenue
Cerner Corporation (NASDAQ: CERN) got off to a solid start in 2017 with its first-quarter results. The healthcare technology giant posted both revenue and earnings at the upper end of its guidance.On
Mighty AstraZeneca Takes a Lickin' on Failed Mystic Trial
When AstraZeneca (NYSE: AZN) spurned overtures from Pfizer (NYSE: PFE) to combine in one of the biggest merger deals of all time, it told investors not to worry. It had plenty of irons in the fire
Baxter International Inc.'s Revenue Growth Snoozes, but Check Out the Earnings Growth
Baxter (NYSE: BAX) kept with its trend in the second quarter of marginal revenue growth, but included a substantial improvement in spending, resulting in an increase in earnings that once again beat
Did the Checkpoint Inhibitor Bubble Just Burst?
Shares of Agenus (NASDAQ: AGEN), a small-cap cancer immunotherapy company, were down by almost 16% at 1:20 p.m. Thursday as a result of AstraZeneca's (NYSE: AZN) Mystic trial missing its primary
Corning Exceeds Expectations on Optical and Gorilla Glass Strength
Corning Incorporated (NYSE: GLW) announced second-quarter 2017 results on Wednesday morning, easily beating expectations on both the top and bottom lines, thanks to strong showings from both its
Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense
Gilead Sciences (NASDAQ: GILD) is nearing a crossroads of sorts. In short, AbbVie's (NYSE: ABBV) eight-week pan-genotypic hepatitis C combo of glecaprevir and pibrentasvir could emerge as a